Contact this trialFirst, we need to learn more about you.
Radioisotope Therapy
Lu-DOTATATE for Neuroendocrine Cancer
Recruiting1 award
London, Ontario
This trial will evaluate the efficacy and safety of Lutetium-177 Octreotate, a treatment for neuroendocrine tumors, in 195 patients. Eligible patients will undergo a diagnostic Ga 68 PET scan, and those who show somatostatin will receive 4 cycles of Lu-DOTATATE treatment. Dose adjustment will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated for progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive treatment but will be followed until progression and acts as control
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.